Comparison of efficacy and cost-effectiveness of two different recombinant human thrombopoietin regimens in prevention and treatment of chemotherapy-induced thrombocytopenia in patients with lung cancer
Objective To investigate the efficacy and cost-effectiveness of different recombinant human thrombopoietin(rhTPO)regimens for the prevention and treatment of chemotherapy-induced thrombocytopenia(CIT)in patients with lung cancer.Methods The clinical data of 73 patients with platelet(PLT)counts under 75×109·L-1 after chemotherapy for lung cancer admitted to the First Affiliated Hospital of Chengdu Medical College from January 2020 to December 2023 were retrospectively analyzed.The patients were divided into the plan 1 group(n=34,300 U·kg-1,qod)and the plan 2 group(n=39,300 U·kg-1,qd)according to different rhTPO treatment regimens.Then the PLT count,adverse reactions and clinical cost-effectiveness ratio were compared between the two groups.Results PLT values at the 3rd,5th,7th and 10th d of drug administration,and the time taken to rise to 100×109·L-1 yielded no statistical difference between the two groups(P>0.05),and the peak PLT values was(103.7±45.3)×109·L-1 in the plan 1 group and(110.2±41.3)×109·L-1 in the plan 2 group,showing no statistical difference(P>0.05).No statistical difference was reported between two groups in incidence of adverse reactions including leukopenia,anemia and malignant vomiting(70.6%vs 56.4%,29.4%vs 23.1%,23.5%vs 17.9%,χ2=1.269,0.572,0.847,both P>0.05).The total treatment cost and rhTPO cost of the plan 1 group were lower than those of the plan 2 group((11.87±4.09)ten-thousand-yuan vs(13.79±5.23)ten-thousand-yuan,(4 236.7±2 906.3)yuan vs(6 872.4±3 673.5)yuan,t=7.154,3.269,both P<0.05).For each unit of improvement in efficacy,the plan 1 group reduced treatment costs by 724.3 yuan as compared with the plan 2 group.Conclusion The efficacy and adverse effects of using 300 U·kg-1 rhTPO daily or every other day for the prevention and treatment of chemotherapy-induced CIT in lung cancer are comparable,while the use of rhTPO every other day can significantly reduce the economic burden of patients.
Recombinant human thrombopoietinLung cancerChemotherapyThrombocytopeniaEconomics
NETL
NSTL
万方数据
